online ISSN 2415-3176
print ISSN 1609-6371
logoExperimental and Clinical Physiology and Biochemistry
  • 6 of 7
Up
ECPB 2021, 93(3): 48–53
https://doi.org/10.25040/ecpb2021.03-04.048
Research articles

Dynamics of changes in hormonal indicators of ovarian reserve in serial application of cyclophosphamide in the experiment

V.A. SHAMRAI 1,2 , O.I. MISIURKO 1,2 , D.I. GREBENIUK 1 , I.V. TARAN 1
Abstract

The aim of the study was to study the dynamics of changes in hormonal parameters of the ovarian reserve during serial use of cyclophosphamide in the experiment. The experiments were performed on 45 adult female white rats. Levels of antimullerian hormone, estradiol and follicle-stimulating hormone were studied. In total, 4 courses of chemotherapy were performed with an interval of 3 weeks. After each course of chemotherapy, the hormonal status of the experimental animals was studied twice: during the first proestrus after the course (to determine the acute ovarian toxicity of the drug) and during the last proestrus before the next course of chemotherapy (to study ovarian function). The dynamics of ovarian reserve hormone levels during serial administration of cyclophosphamide was characterized by wavy dynamics with deterioration immediately after chemotherapy and partial recovery during the period between adjacent courses. Ovariotoxicity of cyclophosphamide when administered serially in therapeutic doses in the experiment was manifested by significant changes in the levels of antimullerian hormone, estradiol and follicle-stimulating hormone after the first course of chemotherapy.

Keywords: cyclophosphamide, antimullerian hormone, estradiol, folliclestimulating hormone, rats

Full text: PDF (Ukr) 1.58M

References
  1. 1. Ahlmann M, Hempel G. The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy. Cancer Chemother Pharmacol. 2016 Oct;78(4):661-71.
  2. 2. Voelcker G. The Mechanism of Action of Cyclophosphamide and Its Consequences for the Development of a New Generation of Oxazaphosphorine Cytostatics. Sci. Pharm. 2020;88:42.
  3. 3. Iqubal A, Iqubal MK, Sharma S, Ansari MA, Najmi AK, Ali SM, Ali J, Haque SE. Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: Old drug with a new vision. Life Sci. 2019 Feb 1;218:112-131. doi: 10.1016/j.lfs.2018.12.018. Epub 2018 Dec 12.
  4. 4. Iqubal A, Syed MA, Najmi AK, Azam F, Barreto GE, Iqubal MK, Ali J, Haque SE. Nano-engineered nerolidol loaded lipid carrier delivery system attenuates cyclophosphamide neurotoxicity - Probable role of NLRP3 inflammasome and caspase-1. Exp Neurol. 2020 Dec;334:113464. doi: 10.1016/j.expneurol.2020.113464. Epub 2020 Sep 15.
  5. 5. Tran A, Bournerias F, Le Beller C, Mir O, Rey E, Pons G, Delahousse M, Tréluyer JM. Serious haematological toxicity of cyclophosphamide in relation to CYP2B6, GSTA1 and GSTP1 polymorphisms. Br J Clin Pharmacol. 2008 Feb;65(2):279-80.
  6. 6. Russo F, Linsalata M, Clemente C, D'Attoma B, Orlando A, Campanella G, Giotta F, Riezzo G. The effects of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study. BMC Cancer. 2013 Feb 4;13:56.
  7. 7. Marcozzi S, Rossi V, Salvatore G, Di Rella F, De Felici M, Klinger FG. Distinct effects of epirubicin, cisplatin and cyclophosphamide on ovarian somatic cells of prepuberal ovaries. Aging (Albany NY). 2019 Nov 11;11(22):10532-10556.
  8. 8. Hao X, Anastácio A, Viñals-Ribé L, Santamaria Lacuesta A, Diakaki C, Alonso de Mena S, Liu K, Rodriguez-Wallberg KA. Follicle Rescue From Prepubertal Ovaries After Recent Treatment With Cyclophosphamide-An Experimental Culture System Using Mice to Achieve Mature Oocytes for Fertility Preservation. Front Oncol. 2021 Sep 24;11:682470.
  9. 9. Pascuali N, Scotti L, Di Pietro M, Oubiña G, Bas D, May M, Gómez Muñoz A, Cuasnicú PS, Cohen DJ, Tesone M, Abramovich D, Parborell F. Ceramide-1-phosphate has protective properties against cyclophosphamide-induced ovarian damage in a mice model of premature ovarian failure. Hum Reprod. 2018 May 1;33(5):844-859.
  10. 10. Elkady MA, Shalaby S, Fathi F, El-Mandouh S. Effects of quercetin and rosuvastatin each alone or in combination on cyclophosphamide-induced premature ovarian failure in female albino mice. Hum Exp Toxicol. 2019 Nov;38(11):1283-1295.
  11. 11. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Pharmaceuticals. Lyon (FR): International Agency for Research on Cancer; 2012. (IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, No. 100A.)
  12. 12. Practice Committee of the American Society for Reproductive Medicine. Electronic address: asrm@asrm.org; Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2020 Dec;114(6):1151-1157.
  13. 13. Fu XY, Chen HH, Zhang N, Ding MX, Qiu YE, Pan XM, Fang YS, Lin YP, Zheng Q, Wang WQ. Effects of chronic unpredictable mild stress on ovarian reserve in female rats: Feasibility analysis of a rat model of premature ovarian failure. Mol Med Rep. 2018 Jul;18(1):532-540.
  14. 14. Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016 Mar;7(2):27-31.
  15. 15. Lee EH, Han SE, Park MJ, Kim HJ, Kim HG, Kim CW, Joo BS, Lee KS. Establishment of Effective Mouse Model of Premature Ovarian Failure Considering Treatment Duration of Anticancer Drugs and Natural Recovery Time. J Menopausal Med. 2018 Dec;24(3):196-203.


Програмування - Roman.im